Noteworthy

Oct 31, 2016
Michael Gordon charts the evolution of regulatory operations and suggests how it can spearhead opportunities for innovation in pharma data.
Oct 27, 2016
The FDA approved Sarepta’s Exondys for Duchenne muscular dystrophy despite little evidence of efficacy.
Oct 24, 2016
Pharmaceutical Executive
Pharm Exec examines the evolving role of the chief financial officer as not just a numbers and bottom-line risk manager but an integral contributor to overall corporate strategy and close partner to the CEO.
Oct 24, 2016
Pharmaceutical Executive
A practical roadmap for pharma brand teams in avoiding the pitfalls in statistical thinking when appraising and presenting data.
Oct 20, 2016
Pharmaceutical Executive
When lobbying tips the scales: a path to drug approval. By Casey McDonald.
Oct 13, 2016
Pharmaceutical Executive
Pharm Exec convenes an expert Roundtable to discuss one of the hottest topics in big data today.
Oct 13, 2016
Pharmaceutical Executive
The latest price rules revision is both radical and rare by the government’s usual exhaustive standards. What do they mean for pharma players in the world’s third-largest market?
Oct 07, 2016
Despite notable deficiencies in the frameworks for assessing the value of prescription drugs, these initiatives are expected to have a major impact on drug utilization and reimbursement.
Oct 07, 2016
Pharmaceutical Executive
Pharm Exec’s 9th annual list of rising industry leaders illustrates how the deployment of essential human capital has changed in line with a business model that is no longer static and predictable—or complacent.
Sep 22, 2016
The UK is moving closer to aligning its two approaches to regulating drug pricing — the voluntary PPRS and statutory price cuts — but the headaches are likely to continue, writes Leela Barham.
native1_300x100
lorem ipsum